Targeting TMEM16A-encoded Ca²⁺-activated Cl^- channels: a new paradigm for antihypertensive therapy?

Area of Science:

• Cardiovascular Pharmacology
• Molecular Biology
• Hypertension Research

Background:

• Hypertension is a major global health concern, significantly increasing the risk of cardiovascular diseases like heart attack and stroke.
• Existing antihypertensive medications often cause adverse effects, necessitating the development of novel therapeutic agents.
• Transmembrane member 16A (TMEM16A)-encoded calcium-activated chloride channels are implicated in vascular smooth muscle function and blood pressure regulation.

Purpose of the Study:

• To investigate the antihypertensive effects of a novel molecule, TMinh-23 (2-bromodifluoroacetylamino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid o-tolylamide).
• To elucidate the mechanism of action of TMinh-23 in reducing blood pressure.
• To evaluate TMinh-23 as a potential therapeutic tool for managing systemic hypertension.

Main Methods:

• Utilized the spontaneously hypertensive rat (SHR) model to assess the in vivo antihypertensive efficacy of TMinh-23.
• Investigated the molecular target of TMinh-23 by examining its effect on transmembrane member 16A (TMEM16A)-encoded calcium-activated chloride channels.
• Analyzed the impact of TMinh-23 on vascular myocytes isolated from resistance arteries.

Main Results:

• TMinh-23 demonstrated a significant reduction in blood pressure in spontaneously hypertensive rats.
• The antihypertensive effect of TMinh-23 was attributed to the inhibition of TMEM16A calcium-activated chloride channels.
• TMinh-23 specifically targeted these channels in vascular myocytes of resistance arteries.

Conclusions:

• TMinh-23 exhibits a promising antihypertensive profile in a preclinical model.
• Inhibition of TMEM16A channels represents a viable mechanism for blood pressure lowering.
• TMinh-23 holds potential as a novel therapeutic agent for hypertension, pending further validation.